Is there an oral tirzepatide? Here's the honest answer

Step 1: Understand what tirzepatide actually is, and why an oral form is harder to make

Tirzepatide is a large peptide molecule that activates both the GIP and GLP-1 gut-hormone receptors, slowing gastric emptying and reducing appetite. It is a dual-agonist: the only licensed weight-loss medicine in the UK that works across two separate pathways at once. Making it injectable was the straightforward part. Making it survive the stomach acid and digestive enzymes that would normally destroy it before it reaches the bloodstream is the genuine pharmaceutical problem Eli Lilly is trying to solve, and you can read a full breakdown of how that challenge is being approached on our tirzepatide oral form page.

Phase 1 and phase 2 trials on oral tirzepatide have produced encouraging data on weight reduction and glucose control. Phase 3 trials began enrolling in 2024. But no full phase 3 results have been published, no marketing authorisation has been submitted to the MHRA, and no NICE appraisal has started. A realistic timeline to a licensed oral tirzepatide in the UK is measured in years, not months. Anyone claiming otherwise is speculating.

If you want a grounded picture of what the injection currently delivers, the Mounjaro page sets out the licensed strengths, how titration works, and the trial evidence behind it.

Step 2: Know the one oral GLP-1 that IS licensed for UK weight management right now

If the idea of a weekly injection is putting you off, you are not alone. It's one of the most common things people bring up when they first look into weight-loss treatment, and it's a completely reasonable concern.

On 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) as the first oral GLP-1 medicine licensed in the UK for weight management. This is a different molecule from tirzepatide: semaglutide targets only the GLP-1 receptor, not GIP. The trial evidence (OASIS 4, 64 weeks, 307 adults) showed roughly 13.6% average weight loss compared with around 2.4% for placebo. Among participants who stayed fully adherent throughout, the figure was closer to 17%.

The tablet is taken once daily, first thing in the morning, before any food or drink other than a small amount of plain water, with at least 30 minutes before eating. No refrigeration is needed. For full dosing details, the prescribing information published by the MHRA is the authoritative source. You can find more background on how the oral tirzepatide question relates to the Wegovy pill on a dedicated page.

Whether oral semaglutide is the right fit for you depends on your health profile, your BMI, and any other medicines you take. It is a prescription-only medicine: a clinical assessment comes before anything else.

Step 3: Compare what's actually on offer (injection versus oral) for your own decision

People often search for an oral tirzepatide hoping to sidestep needles while keeping the stronger weight-loss data that Mounjaro has shown in trials. SURMOUNT-1 reported around 20–21% average body-weight reduction at the highest dose over 72 weeks, and the SURMOUNT-5 head-to-head published in the New England Journal of Medicine found greater average weight loss with tirzepatide than with semaglutide 2.4mg. Oral semaglutide at its 25mg maintenance dose has not been tested head-to-head against Mounjaro.

So the honest picture is this: Mounjaro (injected tirzepatide) has the strongest weight-loss evidence of any currently licensed UK medicine for this purpose, but it is injectable. Oral semaglutide (Wegovy tablets) offers a needle-free route, with good trial results, but lower average weight loss than the highest Mounjaro doses. If you are curious about whether there is an oral version of tirzepatide or Zepbound that might work for your situation, that question is worth exploring in full before making any decisions.

The NHS also recognises tirzepatide's clinical evidence: NICE recommended it in TA1026 (published December 2024) for adults with a BMI of 35 or above and at least one weight-related comorbidity, through a phased NHS rollout. Private access through a regulated pharmacy has no waiting list, but clinical suitability still applies. A summary of what the current cost of Mounjaro looks like in the private market is on the Mounjaro prices page.

Step 4: What to do while you wait for science to catch up

Oral tirzepatide may eventually reach UK patients. It may prove comparably effective to the injection; it may not. Until phase 3 data are published and regulators have reviewed them, no one can say. If you have been wondering whether a pill form of tirzepatide exists, the NHS guidance on tirzepatide on the NHS medicines pages reflects the current licensed position: injection only.

If you are ready to explore what is available today, the sensible path is a proper clinical assessment. A prescriber can look at your BMI, medical history and preferences, and point you toward whichever licensed option is likely to be both suitable and sustainable for you. That conversation is what the consultation is for. There is nothing to book or pay for upfront; the process starts with a free assessment through our weight-loss treatment page, reviewed the same day by a GPhC-registered prescriber.